Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Kohles

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
International Journal of Clinical & Laboratory Research|December 11, 1999
The hololipoprotein complex of beta(2)-glycoprotein I and dicaproyl phosphatidylserineJ D Kohles, M Petersheim, V A DeBari
Drug Design and Discovery|January 7, 2000
Inhibition of beta 2glycoprotein I binding to anionic phospholipids: a strategy for the development of antiphospholipid syndrome-specific drugsJ D Kohles, M Petersheim, V A DeBari
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|May 6, 2008
Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve populationA I Sebba, S Broy, J D Kohles, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 16, 2009
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppressionN Binkley, S L Silverman, C Simonelli, et al.
Applied Biochemistry and Biotechnology|May 18, 1999
Modification of beta 2glycoprotein I by glutardialdehyde. Conformational changes and aggregation accompany exposure of the cryptic autoepitopeM Galazka, M Tang, V A DeBari, et al.
Thrombosis Research|July 31, 1998
A stable, multi-subunit complex of beta2glycoprotein IM Galazka, L B Keil, J D Kohles, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
International Journal of Clinical & Laboratory Research|December 11, 1999
The hololipoprotein complex of beta(2)-glycoprotein I and dicaproyl phosphatidylserineJ D Kohles, M Petersheim, V A DeBari
Drug Design and Discovery|January 7, 2000
Inhibition of beta 2glycoprotein I binding to anionic phospholipids: a strategy for the development of antiphospholipid syndrome-specific drugsJ D Kohles, M Petersheim, V A DeBari
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|May 6, 2008
Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve populationA I Sebba, S Broy, J D Kohles, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 16, 2009
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppressionN Binkley, S L Silverman, C Simonelli, et al.
Applied Biochemistry and Biotechnology|May 18, 1999
Modification of beta 2glycoprotein I by glutardialdehyde. Conformational changes and aggregation accompany exposure of the cryptic autoepitopeM Galazka, M Tang, V A DeBari, et al.
Thrombosis Research|July 31, 1998
A stable, multi-subunit complex of beta2glycoprotein IM Galazka, L B Keil, J D Kohles, et al.
Pageof 1